The goal of this clinical trial is to evaluate whether 10% intranasal lidocaine spray reduces pain and improves the success rate of nasogastric tube (NGT) insertion compared to placebo in adult emergency department patients. The study's primary outcomes were: Procedure success rate (first-pass success) Pain during insertion, measured by the Numeric Rating Scale (NRS), where 0 = "no pain" and 10 = "worst possible pain". The secondary outcomes included: Duration of the procedure (in seconds) Overall success rate (eventual successful insertion regardless of attempts) Pain score at the 5th minute post-procedure (NRS) Patient preference for the same method in future procedures (yes/no) Procedure satisfaction, assessed using an NRS-based score from 0 ("not satisfied at all") to 10 ("completely satisfied"). Participants were randomized to receive either lidocaine or placebo spray intranasally before standard NGT insertion. Pain, success rate, and satisfaction were compared between groups.
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
First-Pass Success Rate
Timeframe: During initial NGT insertion attempt
Insertion pain score
Timeframe: During nasogastric tube insertion